MIGNON LEE-CHEUN LOH
Affiliation: University of California
- Mutations in CBL occur frequently in juvenile myelomonocytic leukemiaMignon L Loh
Department of Pediatrics and the Comprehensive Cancer Center, University of California, San Francisco, California, USA
Blood 114:1859-63. 2009..Moreover, the exclusivity of CBL mutations with respect to other Ras pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway in JMML...
- Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemiaMignon L Loh
Department of Pediatrics and the Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
Br J Haematol 152:677-87. 2011..This review outlines our understanding of the genetic underpinnings of JMML with a recent update on the discovery of novel CBL mutations, as well as a brief review on current therapeutic approaches...
- Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01Mignon L Loh
Department of Pediatrics, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
Blood 107:4508-13. 2006..However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients...
- Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemiaMignon L Loh
Department of Pediatrics and the Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
Hematology Am Soc Hematol Educ Program 2010:357-62. 2010..This review is focused on the genetic abnormalities that occur in JMML, with particular attention to germ-line predisposition syndromes associated with the disorder. Current approaches to therapy are also discussed...
- TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approachesMignon L Loh
Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, California 94143 0519, USA
Curr Opin Hematol 9:345-52. 2002..Incorporating knowledge of this gene rearrangement into treatment decisions serves as a paradigm for translating molecular discoveries into clinically meaningful data to direct patient care and improve outcome...
- Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesisMignon L Loh
Department of Pediatrics, University of California, Rm HSE 302 Box 0519, San Francisco, CA 94143, USA
Blood 103:2325-31. 2004..We conclude that SHP-2 is an important cellular PTPase that is mutated in myeloid malignancies. Further investigation is required to clarify how these mutant proteins interact with Ras and other effectors to deregulate myeloid growth...
- Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, BostonMignon L Loh
Department of Pediatric Hematology Oncology, University of California San Francisco, San Francisco, CA 94143 0519, USA
J Pediatr Hematol Oncol 24:722-6. 2002..To retrospectively evaluate the treatment and outcome of patients diagnosed with infantile fibrosarcoma at the Dana-Farber Cancer Institute and Children's Hospital, Boston...
- The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative diseaseChristian P Kratz
University of California, Room HSE 302 Box 0519, San Francisco, CA 94143, USA
Blood 106:2183-5. 2005..This supports the need to characterize the spectrum of hematologic abnormalities in individuals with NS and to better define the impact of the PTPN11 lesion on the disease course in patients with NS/MPD and JMML...
- Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cellsSuzanne Schubbert
Department of Pediatrics, University of California at San Francisco, 513 Parnassus Ave, HSE 302, San Francisco, CA 94143, USA
Blood 106:311-7. 2005..Mutant SHP-2 proteins induce aberrant growth in multiple hematopoietic compartments, which supports a primary role of hyperactive Ras in the pathogenesis of JMML...
- Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemiaMignon L Loh
Department of Pediatrics, University of California, San Francisco, CA, USA
Leuk Res 29:459-62. 2005..Here, we investigated contribution of PTPN11 mutations to adult MDS and CMML pathogenesis. Our results indicate that PTPN11 lesions might play a role in adult MDS/CMML pathogenesis but do not represent a major molecular event...
- Inherited predispositions and hyperactive Ras in myeloid leukemogenesisJennifer O Lauchle
Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
Pediatr Blood Cancer 46:579-85. 2006..These strains model human disease features and provide an opportunity to investigate novel therapeutic strategies that may ultimately cure JMML and other myeloid malignancies characterized by hyperactive Ras...
- Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium studyMatthew F Gorman
Therapeutic Advances in Childhood Leukemia Consortium, USC CHLA Institute for Pediatric Clinical Research, Los Angeles, California, USA
Pediatr Blood Cancer 55:421-9. 2010..This report highlights efforts to assess the response rates and survival outcomes after first or greater relapse in children with AML...
- Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in CaliforniaCliona M McHale
School of Public Health, University of California, Berkeley 94720 7360, USA
Genes Chromosomes Cancer 37:36-43. 2003..Secondary changes were also similar to those described previously, with deletion of the second TEL allele being the most common. Other secondary changes included duplication of the fusion gene, trisomy 21, and monosomy X...
- Congenital leukemia cutis with subsequent development of leukemiaInga Hofmann Zhang
Department of Pediatrics, University of California San Francisco, California 94143 0519, USA
J Am Acad Dermatol 54:S22-7. 2006..The patient died of refractory leukemia and secondary fungal disease. This case report supports the observation that leukemia cutis with an 11q23 rearrangement should be treated aggressively...
- Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium studyRichard H Ko
Therapeutic Advances in Childhood Leukemia Consortium, Institute for Pediatric Clinical Research and Childrens Center for Cancer and Blood Diseases, University of Southern California Childrens Hospital Los Angeles, Los Angeles, CA, USA
J Clin Oncol 28:648-54. 2010..We sought to define response rates and disease-free survival (DFS) rates in patients treated at TACL institutions, which could serve as a comparator for future studies...
- FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCEMignon Loh; Fiscal Year: 2003..abstract_text> ..
- Ras Pathway Mutations in Human LeukemiaMignon Loh; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..